
Opinion|Videos|April 11, 2025
The Metro Nashville Public Schools Initiative
Experts discuss how to evaluate and communicate the return on investment for continuous glucose monitoring (CGM) coverage to overcome cost-related barriers, explore strategies other payers could adopt based on the success of Metro Nashville Public Schools' initiative to provide CGM devices without prior authorization, and examine the impact of removing prior authorization requirements on appropriate patient selection and utilization, along with which aspects of this model could be adopted by other employers and the resources needed to implement similar programs.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you evaluate and communicate the return on investment for CGM coverage to help overcome cost-related barriers?
- Based on the success of Metro Nashville Public Schools'
initiative to provide CGM devices without prior authorization, what which strategies could other payers adopt, and what challenges might arise in scaling these efforts? - Based on the success of removing prior authorization requirements in the Metro Nashville initiative:
- How did this change impact appropriate patient selection and utilization?
- What Which specific aspects of this model could other employers adopt?
- What resources or support would employers need to implement similar programs?
Advertisement
Related to this article

An employer coalition's new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

Rural patients with HFrEF had lower mortality when treated at urban hospitals but higher early mortality than urban patients at those hospitals.

Report urges payment reform, food policy changes, and wider treatment access, warning that drugs alone can't fix obesity's root causes.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
2
Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives
3
FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR
4
IgA Nephropathy, FSGS Care Needs Coordinators, Not Just New Drugs
5


